20 May 2013
Keywords: idera, pharma, extends, tlr, program, massachusetts, usa-based
Article | 22 May 2006
Massachusetts, USA-based Idera Pharmaceuticals says that it is expanding its portfolio of drug candidates which target Toll-like receptors (TLR)
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 May 2006
17 May 2013
© 2013 thepharmaletter.com